Jade Biosciences, Inc. (JBIO)

NASDAQ: JBIO · Real-Time Price · USD
8.28
-0.05 (-0.60%)
At close: Jul 25, 2025, 4:00 PM
8.27
-0.01 (-0.12%)
After-hours: Jul 25, 2025, 7:17 PM EDT
-0.60%
Market Cap267.56M
Revenue (ttm)n/a
Net Income (ttm)-93.96M
Shares Out 32.24M
EPS (ttm)-18.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume74,574
Open8.46
Previous Close8.33
Day's Range7.90 - 8.46
52-Week Range1.61 - 13.50
Betan/a
AnalystsStrong Buy
Price Target15.50 (+86.75%)
Earnings DateAug 5, 2025

About JBIO

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2024
Employees 30
Stock Exchange NASDAQ
Ticker Symbol JBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 86.75% from the latest price.

Price Target
$15.5
(86.75% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Jade Biosciences to Participate in Two Upcoming Investor Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...

17 days ago - GlobeNewsWire

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

24 days ago - GlobeNewsWire

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 sh...

6 weeks ago - GlobeNewsWire

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

7 weeks ago - GlobeNewsWire

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to ent...

2 months ago - GlobeNewsWire

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

2 months ago - GlobeNewsWire